Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01660451
Registration number
NCT01660451
Ethics application status
Date submitted
6/08/2012
Date registered
8/08/2012
Titles & IDs
Public title
Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas
Query!
Scientific title
Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas
Query!
Secondary ID [1]
0
0
2012-002602-52
Query!
Secondary ID [2]
0
0
16349
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Lymphoma, Non-Hodgkin
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Query!
Cancer
0
0
0
0
Query!
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Copanlisib (Aliqopa, BAY80-6946)
Experimental: Copanlisib (indolent NHL) - Part A: Participants in this arm will be patients with indolent NHL.
Experimental: Copanlisib (aggressive NHL) - Part A: Participants in this arm will be patients with aggressive NHL.
Experimental: Copanlisib (indolent B-cell NHL) - Part B: Participants in this arm will be patients with indolent B-cell NHL.
Treatment: Drugs: Copanlisib (Aliqopa, BAY80-6946)
BAY 80-6946 is administered in a normal saline solution, 100 mL, intravenously over 1h. No intravenous glucose preparations should be administered on the days of infusion. Dosing is weekly for the first 3 weeks (on Days 1, 8, and 15) of a 28-day cycle, followed by a 1-week break (i.e., no infusion on Day 22).
Part A: The individual dose will be 0.8 mg/kg (max. 65 mg) per infusion from Cycle 1 on. The maximum dose of 65 mg should never be exceeded.
Part B: The individual dose will be 60 mg per infusion from Cycle 1 on.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Objective Response Rate (ORR) Based on Independent Review-Part A
Query!
Assessment method [1]
0
0
Objective response rate was defined as the proportion of participants with a best response rating of complete response (CR), unconfirmed complete response (CRu) or partial response (PR), based on the Report of an International Workshop to Standardize Response Criteria for non-Hodgkins Lymphomas, Cheson, 1999, as evaluated by the Independent Response Adjudication Committee (IRAC). For chronic lymphocytic leukemia (CLL) patients Hallek criteria (2008) were used and assessed by investigator.
Query!
Timepoint [1]
0
0
Baseline up to the last patient has completed the 16 weeks of treatment
Query!
Primary outcome [2]
0
0
ORR Based on Independent Review-Part B
Query!
Assessment method [2]
0
0
Objective response rate was defined as the proportion of participants with a best response rating of CR or PR, based on the International Working Group Revised response Criteria for Malignant Lymphoma, Cheson 2007.
Query!
Timepoint [2]
0
0
Baseline up to the last patient has completed the 16 weeks of treatment
Query!
Primary outcome [3]
0
0
ORR Based on Investigator Assessment-Part A
Query!
Assessment method [3]
0
0
Objective response rate was defined as the proportion of participants with a best response rating of CR, CRu or PR, based on the Report of an International Workshop to Standardize Response Criteria for non-Hodgkins Lymphomas, Cheson, 1999. For CLL patients Hallek criteria (2008) were used and assessed by investigator.
Query!
Timepoint [3]
0
0
Baseline up to the last patient has completed the 16 weeks of treatment
Query!
Primary outcome [4]
0
0
ORR Based on Investigator Assessment-Part B
Query!
Assessment method [4]
0
0
Objective response rate was defined as the proportion of participants with a best response rating of CR or PR, based on the International Working Group Revised response Criteria for Malignant Lymphoma, Cheson 2007.
Query!
Timepoint [4]
0
0
Baseline up to the last patient has completed the 16 weeks of treatment
Query!
Secondary outcome [1]
0
0
Duration of Response (DOR) Based on Independent Review-Part A
Query!
Assessment method [1]
0
0
DOR was defined as the time from the date of the first observed tumor response of CR or PR (whichever was noted earlier) to first subsequent disease progression (either first progressive disease \[PD\], first clinical progression or first AE associated with clinical disease progression) or death caused by disease progression, if this death occurred before progression was documented. All deaths were considered as 'caused by disease progression' except deaths with the reason "other" or "AE not related to disease progression. DOR was evaluated only for patients with at least one tumor response of CR, CRu, or PR. Some patients may have had no report of disease progression nor death caused by disease progression until the date of the LPLV. With regards to DOR, these patients were considered as right censored at the date of their last tumor assessment after first observed tumor response.
Query!
Timepoint [1]
0
0
Baseline up to approximately 6 years
Query!
Secondary outcome [2]
0
0
DOR Based on Independent Review-Part B
Query!
Assessment method [2]
0
0
DOR was defined as the time from the date of the first observed tumor response of CR or PR (whichever was noted earlier) to first subsequent disease progression (either first progressive disease \[PD\], first clinical progression or first AE associated with clinical disease progression) or death caused by disease progression, if this death occurred before progression was documented. All deaths were considered as 'caused by disease progression' except deaths with the reason "other" or "AE not related to disease progression. DOR was evaluated only for patients with at least one tumor response of CR, CRu, or PR. Some patients may have had no report of disease progression nor death caused by disease progression until the date of the LPLV. With regards to DOR, these patients were considered as right censored at the date of their last tumor assessment after first observed tumor response.
Query!
Timepoint [2]
0
0
Baseline up to approximately 9 years 7 months
Query!
Secondary outcome [3]
0
0
DOR Based on Investigator Assessment-Part A
Query!
Assessment method [3]
0
0
DOR was defined as the time from the date of the first observed tumor response of CR or PR (whichever was noted earlier) to first subsequent disease progression (either first progressive disease \[PD\], first clinical progression or first AE associated with clinical disease progression) or death caused by disease progression, if this death occurred before progression was documented. All deaths were considered as 'caused by disease progression' except deaths with the reason "other" or "AE not related to disease progression. DOR was evaluated only for patients with at least one tumor response of CR, CRu, or PR. Some patients may have had no report of disease progression nor death caused by disease progression until the date of the LPLV. With regards to DOR, these patients were considered as right censored at the date of their last tumor assessment after first observed tumor response.
Query!
Timepoint [3]
0
0
Baseline up to approximately 6 years
Query!
Secondary outcome [4]
0
0
DOR Based on Investigator Assessment-Part B
Query!
Assessment method [4]
0
0
DOR was defined as the time from the date of the first observed tumor response of CR or PR (whichever was noted earlier) to first subsequent disease progression (either first progressive disease \[PD\], first clinical progression or first AE associated with clinical disease progression) or death caused by disease progression, if this death occurred before progression was documented. All deaths were considered as 'caused by disease progression' except deaths with the reason "other" or "AE not related to disease progression. DOR was evaluated only for patients with at least one tumor response of CR, CRu, or PR. Some patients may have had no report of disease progression nor death caused by disease progression until the date of the LPLV. With regards to DOR, these patients were considered as right censored at the date of their last tumor assessment after first observed tumor response.
Query!
Timepoint [4]
0
0
Baseline up to approximately 9 years 7 months
Query!
Secondary outcome [5]
0
0
Progression Free Survival (PFS) Based on Independent Review-Part A
Query!
Assessment method [5]
0
0
PFS was defined as the time (in days) from the date of the first treatment to the date of first observed PD (radiological or clinical, or first AE associated with clinical PD, whichever was earlier) or death due to any cause (if death occurred before progression was documented).
Query!
Timepoint [5]
0
0
Baseline up to approximately 6 years
Query!
Secondary outcome [6]
0
0
PFS Based on Independent Review-Part B
Query!
Assessment method [6]
0
0
PFS was defined as the time (in days) from the date of the first treatment to the date of first observed PD (radiological or clinical, or first AE associated with clinical PD, whichever was earlier) or death due to any cause (if death occurred before progression was documented).
Query!
Timepoint [6]
0
0
Baseline up to approximately 9 years 7 months
Query!
Secondary outcome [7]
0
0
PFS Based on Investigator Assessment-Part A
Query!
Assessment method [7]
0
0
PFS was defined as the time (in days) from the date of the first treatment to the date of first observed PD (radiological or clinical, or first AE associated with clinical PD, whichever was earlier) or death due to any cause (if death occurred before progression was documented).
Query!
Timepoint [7]
0
0
Baseline up to approximately 6 years
Query!
Secondary outcome [8]
0
0
PFS Based on Investigator Assessment-Part B
Query!
Assessment method [8]
0
0
PFS was defined as the time (in days) from the date of the first treatment to the date of first observed PD (radiological or clinical, or first AE associated with clinical PD, whichever was earlier) or death due to any cause (if death occurred before progression was documented).
Query!
Timepoint [8]
0
0
Baseline up to approximately 9 years 7 months
Query!
Secondary outcome [9]
0
0
Overall Survival (OS)-Part A
Query!
Assessment method [9]
0
0
OS was defined as the time (in days) from the date of first administration of study treatment to death due to any cause. Patients who were alive at the date of the LPLV were censored at the minimum of the date of LPLV and the last available date of evidence that the patient was still alive.
Query!
Timepoint [9]
0
0
Baseline up to approximately 6 years
Query!
Secondary outcome [10]
0
0
OS-Part B
Query!
Assessment method [10]
0
0
OS was defined as the time (in days) from the date of first administration of study treatment to death due to any cause. OS was defined as the time (in days) from the date of first administration of study treatment to death due to any cause. Patients who were alive at the date of the LPLV were censored at the minimum of the date of LPLV and the last available date of evidence that the patient was still alive.
Query!
Timepoint [10]
0
0
Baseline up to approximately 9 years 7 months
Query!
Secondary outcome [11]
0
0
Functional Assessment of Cancer Therapy - Lymphoma Lymphoma Subscale (FACT-Lym LymS) at Week 16 - Part B
Query!
Assessment method [11]
0
0
HRQoL assessment was used to describe development of patients with copanlisib by using FACT-Lym questionnaire assessment tool. It contains 42 items (questions) covering HRQoL, common lymphoma symptoms and treatment side-effects. The FACT - General (FACT-G) questionnaire contains 27 items covering 4 core HRQoL subscales: Physical Wellbeing (7 items), Social/Family Wellbeing (7), Emotional Wellbeing (6), and Functional Wellbeing (7). The FACT-Lym also includes an Additional Concerns subscale (15 items) (FACT-Lym LymS), addressing issues typically experienced by lymphoma patients. Some of the issues covered include pain, itching, night sweats, trouble sleeping, fatigue and trouble concentrating. FACT-Lym also asks patients about lumps and swelling, fevers, infections, weight, appetite, emotional stability and treatment. Score range for the FACT-Lym LymS was 0 - 60, higher score represent less symptoms. Here in below table "n" signifies evaluable participants for the respective category.
Query!
Timepoint [11]
0
0
Baseline up to week 16
Query!
Secondary outcome [12]
0
0
Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) Total Score at Week 16 - Part B
Query!
Assessment method [12]
0
0
HRQoL assessment was used to describe development of patients with copanlisib by using FACT-Lym questionnaire assessment tool. It contains 42 items (questions) covering HRQoL, common lymphoma symptoms and treatment side-effects. The FACT - General (FACT-G) questionnaire contains 27 items covering 4 core HRQoL subscales: Physical Wellbeing (7 items), Social/Family Wellbeing (7), Emotional Wellbeing (6), and Functional Wellbeing (7). The FACT-Lym also includes an Additional Concerns subscale (15 items) (FACT-Lym LymS), addressing issues typically experienced by lymphoma patients. Some of the issues covered include pain, itching, night sweats, trouble sleeping, fatigue and trouble concentrating. FACT-Lym also asks patients about lumps and swelling, fevers, infections, weight, appetite, emotional stability and treatment. FACT-Lym total score range was 0-168, higher score indicates better HRQoL. Here, in the below table "n" signifies evaluable participants for the respective category.
Query!
Timepoint [12]
0
0
Baseline up to week 16
Query!
Eligibility
Key inclusion criteria
* Indolent NHL:
* Histologically confirmed diagnosis of follicular lymphoma (FL) grades 1, 2 or 3a, marginal zone lymphoma (including nodal or splenic marginal zone B-cell lymphoma and mucosa-associated lymphoid tissue [MALT] lymphoma), lymphoplasmacytic lymphoma/Waldenström macroglobulinemia, chronic lymphocytic leukemia (CLL).
* Relapsed after = 2 prior chemotherapy- or immunotherapy-based regimens for indolent NHL, or refractory to 2 prior chemotherapy and/ or immunotherapy-based regimens.
* Aggressive NHL:
* Histologically confirmed diagnosis of grade 3b follicular lymphoma (FL), transformed indolent lymphoma, diffuse large B-cell lymphoma (DLBCL), mediastinal large B-cell lymphoma, mantle cell lymphoma (MCL), peripheral T-cell lymphoma unspecified, or anaplastic large cell lymphoma primary systemic type, or angioimmunoblastic T cell lymphoma.
* Relapsed after = 2 prior chemotherapy regimens, including the following: First-line treatment with standard anthracycline-containing regimen (e.g., cyclophosphamide, doxorubicin, vincristine, and prednisone or equivalent). At least 1 additional combination chemotherapy regimen. Patients relapsed after or refractory to first prior chemotherapy- and/or immunotherapy-based regimen for aggressive NHL and not eligible for high-dose regimen followed by transplant. High-dose chemotherapy, or chemoradiotherapy with autologous stem cell transplantation is considered 1 regimen. Patients with CD20 expressing neoplastic cells must have received prior rituximab, if available.
* Patients with transformed indolent lymphoma must have received at least 2 prior chemotherapy- and/or immunotherapy-based regimens
* Consent to provide fresh tumor tissue during screening
* Indolent B-cell NHL lymphoma (study part B):
* Histologically confirmed diagnosis of indolent B-cell NHL, with histological subtype limited to the following:
* Follicular lymphoma (FL) grade 1-2-3a
* Small lymphocytic lymphoma (SLL) with absolute lymphocyte count < 5 x 109/L at the time of diagnosis and at study entry
* Lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia (LPL/WM)
* Marginal zone lymphoma (MZL) (splenic, nodal, or extranodal)
* Relapsed or refractory after = 2 prior lines of therapy (refractory defined as not responding to a standard regimen or progressing within 6 months of the last course of a standard regimen). Patients must have received Rituximab and alkylating agents.
* For all patients:
* Male or female patients > 18 years of age
* ECOG performance status = 2 (ECOG: Eastern Cooperative Oncology Group)
* Life expectancy of at least 3 months
* Adequate bone marrow, liver and renal function as assessed within 7 days before starting study treatment
* Left ventricular ejection fraction (LVEF) = lower limit of normal (LLN) for the Institution
* Availability of archival tumor tissue
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Uncontrolled hypertension (blood pressure = 150/90 mmHg despite optimal medical management)
* Patients with evidence or history of bleeding diathesis. Any hemorrhage or bleeding event = CTCAE Grade 3 within 4 weeks of start of study medication (CTCAE: Common Terminology Criteria for Adverse Events).
* History or concurrent condition of interstitial lung disease
* Unresolved toxicity higher than CTCAE grade 1 (NCI-CTC version 4.0) attributed to any prior therapy/procedure excluding alopecia. (NCI: National Cancer Institute)
* Prior treatment with PI3K inhibitors
* Systemic corticosteroid therapy (ongoing)
* Hepatitis B or C. All subjects must be screened for hepatitis B and C up to 28 days prior to study drug start using the hepatitis virus panel laboratorial routine. Subjects positive for HBsAg or HBcAb will be eligible if they are negative for HBV-DNA; subjects positive for HCV IgG will be eligible if they are negative for HCV RNA.
* For Part B:
* Histologically confirmed diagnosis of follicular lymphoma grade 3b or transformed disease and chronic lymphocytic leukemia (CLL)
* History or concurrent condition of interstitial lung disease or severely impaired pulmonary function
* Excluded medical conditions:
* Previous or concurrent cancer that is distinct in primary site or histology from indolent B-cell NHL within 5 years prior to treatment start EXCEPT for curatively treated cervical cancer in situ, nonmelanoma skin cancer and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor invades lamina propria)].
* Hepatitis B or C. All subjects must be screened for hepatitis B and C up to 28 days prior to study drug start using the hepatitis virus panel laboratorial routine. Subjects positive for HBsAg or HBcAb will be eligible if they are negative for HBV-DNA; subjects positive for HCV IgG will be eligible if they are negative for HCV-RNA.
* Type I or II diabetes mellitus with HbA1c > 8.5% or fasting plasma glucose > 160 mg/dL at screening.
* Previous or concurrent cancer that is distinct in primary site or histology from indolent B-cell NHL within 5 years prior to treatment start EXCEPT for curatively treated cervical cancer in situ, nonmelanoma skin cancer and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor invades lamina propria)].
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
19/11/2012
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
18/05/2023
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
227
Query!
Recruitment in Australia
Recruitment state(s)
ACT
Query!
Recruitment hospital [1]
0
0
- Garran
Query!
Recruitment postcode(s) [1]
0
0
2605 - Garran
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Kentucky
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Michigan
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Minnesota
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
New York
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
North Carolina
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Ohio
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Texas
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Washington
Query!
Country [14]
0
0
Austria
Query!
State/province [14]
0
0
Linz
Query!
Country [15]
0
0
Belgium
Query!
State/province [15]
0
0
Bruxelles - Brussel
Query!
Country [16]
0
0
Belgium
Query!
State/province [16]
0
0
Bruxelles
Query!
Country [17]
0
0
Belgium
Query!
State/province [17]
0
0
Gent
Query!
Country [18]
0
0
Belgium
Query!
State/province [18]
0
0
Leuven
Query!
Country [19]
0
0
Belgium
Query!
State/province [19]
0
0
Turnhout
Query!
Country [20]
0
0
Belgium
Query!
State/province [20]
0
0
Wilrijk
Query!
Country [21]
0
0
Bulgaria
Query!
State/province [21]
0
0
Sofia
Query!
Country [22]
0
0
Canada
Query!
State/province [22]
0
0
New Brunswick
Query!
Country [23]
0
0
Canada
Query!
State/province [23]
0
0
Quebec
Query!
Country [24]
0
0
Finland
Query!
State/province [24]
0
0
Helsinki
Query!
Country [25]
0
0
Finland
Query!
State/province [25]
0
0
Oulu
Query!
Country [26]
0
0
Finland
Query!
State/province [26]
0
0
Tampere
Query!
Country [27]
0
0
Finland
Query!
State/province [27]
0
0
Turku
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Brest
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Creteil
Query!
Country [30]
0
0
France
Query!
State/province [30]
0
0
La Roche Sur Yon
Query!
Country [31]
0
0
France
Query!
State/province [31]
0
0
Lille
Query!
Country [32]
0
0
France
Query!
State/province [32]
0
0
PARIS cedex
Query!
Country [33]
0
0
France
Query!
State/province [33]
0
0
Pessac
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Pierre Benite
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Poitiers
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Rouen
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Vandoeuvre-les-nancy
Query!
Country [38]
0
0
Germany
Query!
State/province [38]
0
0
Bayern
Query!
Country [39]
0
0
Germany
Query!
State/province [39]
0
0
Berlin
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
Nordrhein-Westfalen
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Rheinland-Pfalz
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Sachsen
Query!
Country [43]
0
0
Greece
Query!
State/province [43]
0
0
Athens
Query!
Country [44]
0
0
Hong Kong
Query!
State/province [44]
0
0
Hong Kong
Query!
Country [45]
0
0
Hong Kong
Query!
State/province [45]
0
0
Shatin
Query!
Country [46]
0
0
Hungary
Query!
State/province [46]
0
0
Budapest
Query!
Country [47]
0
0
Hungary
Query!
State/province [47]
0
0
Kaposvar
Query!
Country [48]
0
0
Ireland
Query!
State/province [48]
0
0
Galway
Query!
Country [49]
0
0
Israel
Query!
State/province [49]
0
0
Petach Tikva
Query!
Country [50]
0
0
Israel
Query!
State/province [50]
0
0
Ramat Gan
Query!
Country [51]
0
0
Israel
Query!
State/province [51]
0
0
Zerifin
Query!
Country [52]
0
0
Italy
Query!
State/province [52]
0
0
Campania
Query!
Country [53]
0
0
Italy
Query!
State/province [53]
0
0
Emilia-Romagna
Query!
Country [54]
0
0
Italy
Query!
State/province [54]
0
0
Lazio
Query!
Country [55]
0
0
Italy
Query!
State/province [55]
0
0
Lombardia
Query!
Country [56]
0
0
Italy
Query!
State/province [56]
0
0
Piemonte
Query!
Country [57]
0
0
Korea, Republic of
Query!
State/province [57]
0
0
Busan Gwang''yeogsi
Query!
Country [58]
0
0
Korea, Republic of
Query!
State/province [58]
0
0
Seoul Teugbyeolsi
Query!
Country [59]
0
0
Korea, Republic of
Query!
State/province [59]
0
0
Seoul
Query!
Country [60]
0
0
New Zealand
Query!
State/province [60]
0
0
Christchurch
Query!
Country [61]
0
0
Poland
Query!
State/province [61]
0
0
Gdynia
Query!
Country [62]
0
0
Poland
Query!
State/province [62]
0
0
Krakow
Query!
Country [63]
0
0
Portugal
Query!
State/province [63]
0
0
Lisboa
Query!
Country [64]
0
0
Russian Federation
Query!
State/province [64]
0
0
Kemerovo
Query!
Country [65]
0
0
Russian Federation
Query!
State/province [65]
0
0
Moscow
Query!
Country [66]
0
0
Russian Federation
Query!
State/province [66]
0
0
Nizhny Novgorod
Query!
Country [67]
0
0
Russian Federation
Query!
State/province [67]
0
0
Omsk
Query!
Country [68]
0
0
Russian Federation
Query!
State/province [68]
0
0
Saratov
Query!
Country [69]
0
0
Russian Federation
Query!
State/province [69]
0
0
St. Petersburg
Query!
Country [70]
0
0
Singapore
Query!
State/province [70]
0
0
Singapore
Query!
Country [71]
0
0
Spain
Query!
State/province [71]
0
0
Madrid
Query!
Country [72]
0
0
Spain
Query!
State/province [72]
0
0
Málaga
Query!
Country [73]
0
0
Spain
Query!
State/province [73]
0
0
Barcelona
Query!
Country [74]
0
0
Spain
Query!
State/province [74]
0
0
Sevilla
Query!
Country [75]
0
0
Spain
Query!
State/province [75]
0
0
Valencia
Query!
Country [76]
0
0
Sweden
Query!
State/province [76]
0
0
Uddevalla
Query!
Country [77]
0
0
Turkey
Query!
State/province [77]
0
0
Ankara
Query!
Country [78]
0
0
Turkey
Query!
State/province [78]
0
0
Istanbul
Query!
Country [79]
0
0
Turkey
Query!
State/province [79]
0
0
Izmir
Query!
Country [80]
0
0
United Kingdom
Query!
State/province [80]
0
0
Cambridgeshire
Query!
Country [81]
0
0
United Kingdom
Query!
State/province [81]
0
0
Devon
Query!
Country [82]
0
0
United Kingdom
Query!
State/province [82]
0
0
Hampshire
Query!
Country [83]
0
0
United Kingdom
Query!
State/province [83]
0
0
London
Query!
Country [84]
0
0
United Kingdom
Query!
State/province [84]
0
0
Merseyside
Query!
Country [85]
0
0
United Kingdom
Query!
State/province [85]
0
0
Surrey
Query!
Country [86]
0
0
United Kingdom
Query!
State/province [86]
0
0
West Midlands
Query!
Country [87]
0
0
United Kingdom
Query!
State/province [87]
0
0
Leeds
Query!
Country [88]
0
0
United Kingdom
Query!
State/province [88]
0
0
Manchester
Query!
Country [89]
0
0
United Kingdom
Query!
State/province [89]
0
0
Romford
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Bayer
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The objective of the study (part A) is to evaluate the efficacy and safety of BAY80-6946 in patients with indolent or aggressive Non-Hodgkin's Lymphoma, who have progressed after standard therapy. 30 patients will be enrolled to both indolent and aggressive disease group. The objective of the study part B (CHRONOS-1) is to evaluate the efficacy and safety of BAY80-6946 in patients with relapsed/refractory follicular lymphoma. 120 patients will be enrolled in the part B of the study. Further objectives are to evaluate the pharmacokinetics and biomarkers. Quality of life will be a further objective of part B of the study. In a cohort of 20 patients (enrolled both in part A and B) an ECG substudy will be performed to assess the potential for cardiac toxicity and QT/QTc interval prolongation of BAY80-6946. After an up to 28-day screening period, eligible patients will start treatment with BAY80-6946 at a dose of 0.8 mg/kg (Part A) and at a dose of 60 mg (Part B). Treatment will be continued until disease has progressed or until another criterion is met for withdrawal from study. An end-of-treatment visit will be performed within 7 days after discontinuation of study treatment. Thirty to 35 days after last study drug administration, a safety followup visit will be performed for the collection of adverse events (AEs) and concomitant medication data. Patients will be contacted quarterly to determine overall survival status up to 4 years after last patient completed treatment. Patients who discontinue study drug for reasons other than disease progression will enter the Active Assessment Follow-up period. The end of study notification to Health Authorities will be based on the completion of the collection of survival data. The efficacy is measured by the decrease in tumor size. Tumor assessments will be done at Screening, every 8 weeks during Year 1, every 12 weeks during Year 2, and every 6 months during Year 3. Blood samples will be collected for pharmacokinetic analysis. Archival tumor tissue and blood samples will be collected for biomarker analysis (mandatory) and for central pathology review (part B), fresh biopsy tissue will also be collected if available.
Query!
Trial website
https://clinicaltrials.gov/study/NCT01660451
Query!
Trial related presentations / publications
Dreyling M, Morschhauser F, Bouabdallah K, Bron D, Cunningham D, Assouline SE, Verhoef G, Linton K, Thieblemont C, Vitolo U, Hiemeyer F, Giurescu M, Garcia-Vargas J, Gorbatchevsky I, Liu L, Koechert K, Pena C, Neves M, Childs BH, Zinzani PL. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann Oncol. 2017 Sep 1;28(9):2169-2178. doi: 10.1093/annonc/mdx289. Panayiotidis P, Follows GA, Mollica L, Nagler A, Ozcan M, Santoro A, Stevens D, Trevarthen D, Hiemeyer F, Garcia-Vargas J, Childs BH, Zinzani PL, Dreyling M. Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma. Blood Adv. 2021 Feb 9;5(3):823-828. doi: 10.1182/bloodadvances.2020002910.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Bayer Study Director
Query!
Address
0
0
Bayer
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.
Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Type
Citations or Other Details
Journal
Dreyling M, Morschhauser F, Bouabdallah K, Bron D,...
[
More Details
]
Results are available at
https://clinicaltrials.gov/study/NCT01660451